Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Lutikizumab in Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Failure
jRCT2071220012Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of lutikizumab in hidradenitis suppurativa (HS) (4 arms), sponsored by AbbVie Inc. Primary endpoint: HiSCR response at Week 16. Started Oct 2022; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2071220012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220012.